Goldman Sachs is in the spotlight as tech firms test IPO market

Brasil Notícia Notícia

Goldman Sachs is in the spotlight as tech firms test IPO market
Brasil Últimas Notícias,Brasil Manchetes
  • 📰 NBCNewYork
  • ⏱ Reading Time:
  • 13 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 63%

The drought in tech IPOs the past 18 months is about to break — and it’s a key moment for leading advisor Goldman Sachs.

initially to the roughly $55 billion that represents the top end of a target share price of $47 to $51.

Further, Arm is selling an unusually small slice of its overall stock, about 9%, which helps drive scarcity. That small public float means new investors will have fewer rights related to voting power and corporate governance, Trainer noted.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

NBCNewYork /  🏆 270. in US

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Goldman Sachs asset and wealth management executive to retire, as others join firmGoldman Sachs asset and wealth management executive to retire, as others join firmGoldman Sachs Group Inc. executive Laurence Stein is retiring after 27 years at the bank, according to an internal memo seen by MarketWatch. Stein was most...
Consulte Mais informação »

Goldman Sachs discloses short position in Philips after Dutch regulator review By ReutersGoldman Sachs discloses short position in Philips after Dutch regulator review By ReutersGoldman Sachs discloses short position in Philips after Dutch regulator review
Consulte Mais informação »

Hedge funds have bailed on the U.S. consumer in a big way, Goldman Sachs data findsHedge funds have bailed on the U.S. consumer in a big way, Goldman Sachs data findsHedge funds are betting that the U.S. consumer is in for a difficult ride.
Consulte Mais informação »

Goldman Sachs says this blood cancer treatment stock can gain 70% ahead of planned drug launchGoldman Sachs says this blood cancer treatment stock can gain 70% ahead of planned drug launchAnalyst Corinne Jenkins upgraded the firm to buy from neutral and maintained her price target of $4.
Consulte Mais informação »

Walgreens Boots, Goldman Sachs share gains lead Dow's nearly 100-point jumpWalgreens Boots, Goldman Sachs share gains lead Dow's nearly 100-point jumpThe Dow Jones Industrial Average is trading up Tuesday afternoon with shares of Walgreens Boots and Goldman Sachs delivering the strongest returns for the...
Consulte Mais informação »

Goldman Sachs, Walgreens Boots share gains contribute to Dow's 175-point jumpGoldman Sachs, Walgreens Boots share gains contribute to Dow's 175-point jumpShares of Goldman Sachs and Walgreens Boots are trading higher Tuesday afternoon, lifting the Dow Jones Industrial Average into positive territory. The Dow...
Consulte Mais informação »



Render Time: 2025-02-26 19:21:29